Intellia Therapeutics (NTLA) Operating Income (2016 - 2025)
Historic Operating Income for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to -$111.5 million.
- Intellia Therapeutics' Operating Income rose 2299.72% to -$111.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$478.7 million, marking a year-over-year increase of 1096.9%. This contributed to the annual value of -$534.3 million for FY2024, which is 368.18% down from last year.
- Latest data reveals that Intellia Therapeutics reported Operating Income of -$111.5 million as of Q3 2025, which was up 2299.72% from -$110.0 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Operating Income registered a high of -$46.4 million during Q1 2021, and its lowest value of -$144.8 million during Q3 2024.
- Over the past 5 years, Intellia Therapeutics' median Operating Income value was -$112.0 million (recorded in 2023), while the average stood at -$111.5 million.
- Its Operating Income has fluctuated over the past 5 years, first plummeted by 21070.76% in 2022, then soared by 2299.72% in 2025.
- Quarter analysis of 5 years shows Intellia Therapeutics' Operating Income stood at -$80.4 million in 2021, then plummeted by 36.9% to -$110.1 million in 2022, then decreased by 27.07% to -$139.9 million in 2023, then rose by 2.46% to -$136.4 million in 2024, then increased by 18.3% to -$111.5 million in 2025.
- Its last three reported values are -$111.5 million in Q3 2025, -$110.0 million for Q2 2025, and -$120.8 million during Q1 2025.